Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy

LPCN•2026-10-07

Health Canada approved TLANDO capsules for testosterone replacement therapy in adult men with hypogonadism; Verity Pharma holds exclusive North American commercial rights and targets a Canadian launch by the end of 2026.

1. Canadian approval

Health Canada cleared TLANDO capsules for testosterone replacement therapy in adult men with hypogonadism.

2. Commercial plans

Verity Pharma holds exclusive North American commercial rights and targets a Canadian launch by the end of 2026.

Sources

Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy

Sec

Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy

1. Canadian approval

2. Commercial plans

Related News

Microsoft: Yorkville Ives initiates coverage with outperform rating; target price $615.00

NextEra Energy updates financial calendar with Q3 results release and webcast schedule

Yorkville Ives initiates coverage of Netflix with an in-line rating and $75 target

Sources

Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy

Rubrik, Inc.: Yorkville Ives initiates coverage with outperform rating; target price $145.00

Romania signs contract to buy 12 Airbus H225M helicopters